Αποτελέσματα Αναζήτησης
Tarceva® (erlotinib) is a first-generation, selective, reversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (TKI) binding with high affinity to the common EGFR mutations occurring in non-small cell lung cancer (NSCLC), notably exon 19 deletions or exon 21 (L858R) substitution. 1.
- What is Tarceva
EGFR Mut+ NSCLC. Tarceva® is approved in the European Union,...
- Scientific Information
Erlotinib is a standard of care treatment for locally...
- Erlotinib clinical trials
Erlotinib is a selective, reversible tyrosine kinase...
- Erlotinib plus bevacizumab combination studies
ARTEMIS (CTONG 1509) investigator interview video Erlotinib...
- Erlotinib real-world evidence and retrospective analyses
After clinical trials, it is important to understand how...
- Ensure Phase III Trial
NEJ026 phase III trial NEJ026: summary of safety data BELIEF...
- Jo25567 Phase II Trial
ARTEMIS (CTONG 1509) investigator interview video JO25567...
- Optimal Phase III Trial
NEJ026 phase III trial NEJ026: summary of safety data BELIEF...
- What is Tarceva
13 Ιουλ 2009 · Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) who received...
The first study compared Tarceva with chemotherapy in 173 patients with advanced NSCLC with activating EGFR mutations who had not received previous chemotherapy. Patients taking Tarceva lived for an average of 10.4 months without their disease getting worse compared with 5.1 months for those receiving chemotherapy medicines.
Well, it happened again that the first word came from the financial community (report here), as we learned today that a large trial testing the value of maintenance tarceva (erlotinib), the oral EGFR inhibitor, provides a significant improvement in progression-free survival (PFS).
1 Ιαν 2008 · Phase III trial (AVAiL) of bevacizumab with and without chemotherapy for advanced NSCLC: trial design. Abbreviations: NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD, progression of disease; PFS, progression-free survival; TTF, time to treatment failure.
20 Δεκ 2010 · The Tarceva or Chemotherapy (TORCH) study 49 is a Phase III randomized, multicenter trial based on a noninferiority survival comparison between an experimental strategy including first-line erlotinib followed at progression by chemotherapy with cisplatin and gemcitabine (PG) and a standard arm consisting of first-line PG chemotherapy followed ...
7 Νοε 2008 · Tarceva is currently approved as a second-line treatment for patients with advanced NSCLC, who have progressed following treatment with at least one prior chemotherapy regimen, based on a 37...
